Welcome to our dedicated page for Iterum Therapeutics Plc news (Ticker: ITRM), a resource for investors and traders seeking the latest updates and insights on Iterum Therapeutics Plc stock.
Iterum Therapeutics plc (Nasdaq: ITRM) is a pharmaceutical company focused on next generation oral and IV antibiotics designed to treat infections caused by multi-drug resistant pathogens in community and hospital settings. Its news flow centers on the development, approval and commercialization of sulopenem-based therapies, particularly the oral product ORLYNVAH™.
Company press releases highlight regulatory milestones, including U.S. Food and Drug Administration approval of ORLYNVAH™ (oral sulopenem) for adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis who have limited or no alternative oral antibacterial options. News items also cover the U.S. commercial launch of ORLYNVAH™ and its rollout into the community market through a commercialization partnership with EVERSANA Life Science Services, LLC.
Investors and observers following ITRM news will see updates on market access and reimbursement, such as contracts with group purchasing organizations working with major pharmacy benefit managers (PBMs), rebate agreements with Medicare Part D PBMs, and coverage developments across commercial, Medicare and government plans. Additional coverage includes specialty distribution arrangements with McKesson and Cencora, which enable physicians to obtain ORLYNVAH™ through preferred channels.
Iterum’s news stream also features patent estate developments in regions such as China, Mexico, Canada, Europe and Japan, as well as scientific presentations at conferences like IDWeek and publication of Phase 3 trial data in NEJM Evidence. Financial result announcements, at-the-market equity offering updates and Nasdaq listing compliance notices provide further context on the company’s capital markets activity.
For those tracking Iterum Therapeutics, the ITRM news page offers a consolidated view of clinical, regulatory, commercial, intellectual property and listing-related announcements that shape the company’s progress in the anti-infective space.
Iterum Therapeutics plc (Nasdaq: ITRM) reported its Q2 2020 financial results, highlighting a net loss of $12.5 million, a significant improvement from the $27.6 million loss in Q2 2019. Cash and cash equivalents stood at $12.3 million, supplemented by $4.4 million from a registered direct offering in July 2020. The company achieved one primary endpoint in its uUTI trial but failed in its cUTI trial. A meeting with the FDA is scheduled for Q3 2020 to discuss regulatory options for sulopenem. Overall R&D expenses dropped to $5.0 million, reflecting reduced clinical trial activities.
Iterum Therapeutics plc (Nasdaq: ITRM) announced a planned rights offering to raise up to $8.4 million, following a private placement of senior subordinated notes. The record date for the rights offering is set for August 5, 2020. Each eligible shareholder will receive one non-transferable subscription right per ordinary share owned, allowing them to purchase up to 8,400 units at a subscription price of $1,000 per unit. The subscription period is expected to start on August 11, 2020, lasting at least 20 days. Details will follow after the SEC registration statement becomes effective.
Iterum Therapeutics has entered into agreements for the purchase of 3,372,686 ordinary shares at $1.4825 each in a registered direct offering, totaling approximately $5.0 million. Concurrently, unregistered warrants to purchase up to 1,686,343 ordinary shares will be issued with an exercise price of $1.42 per share. Proceeds will support continued clinical development of sulopenem and general corporate purposes. The offering is set to close around July 2, 2020, pending customary conditions.
Iterum Therapeutics plc (Nasdaq: ITRM) announced the successful passing of all resolutions at its Annual General Meeting on June 10, 2020. A significant resolution allowed Sarissa Capital Management's funds to potentially acquire up to 60% of the company's ordinary shares through the exchange of $15 million of Exchangeable Senior Subordinated Notes. The resolution received 6,808,330 votes in favor and 199,749 against. The Sarissa Notes could result in the issuance of approximately 15 million new shares.
Iterum Therapeutics (Nasdaq: ITRM) announced a registered direct offering to institutional investors, selling 2,971,770 ordinary shares at $1.6825 each. The concurrent private placement includes unregistered warrants for 1,485,885 shares, exercisable at $1.62 per share. Gross proceeds are expected to reach $5 million, which will fund the ongoing Phase 3 trial of sulopenem for uUTI, regulatory filings, and general corporate expenses. The closing date is anticipated around June 5, 2020, subject to customary conditions.
Iterum Therapeutics (Nasdaq: ITRM) announced that its sulopenem did not achieve statistical non-inferiority to ertapenem in the SURE 2 trial for complicated urinary tract infection (cUTI). The trial involved 1,395 patients, and responder rates were 67.8% for sulopenem versus 73.9% for ertapenem, showing a -6.1% difference. Following these disappointing results, the company is evaluating strategic and financial alternatives, including potential asset sales or restructuring. Sulopenem has shown tolerability, with ongoing development in other areas, but the recent trial outcome raises concerns for stakeholders.
Iterum Therapeutics (ITRM) reported Q1 2020 financial results, highlighting a net loss of $16.1 million, an improvement from $20.6 million in Q1 2019. The company raised $51.6 million through a private placement to strengthen its balance sheet, with cash and equivalents totaling $23.3 million. R&D expenses decreased to $9.7 million, reflecting reduced clinical trial costs as Phase 3 trials for sulopenem near completion. Topline results for complicated and uncomplicated urinary tract infections (cUTI and uUTI) are expected in Q2 2020, signaling potential growth opportunities.